---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145360"
form_type: "8-K/A"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:54:20.176015+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical corrects Q1 revenue to $10.6M, net loss $9.2M in 8-K/A amendment

## Summary
- Revenue $10.6M (U.S. Dollars); net loss $9.2M, $0.37 per share for quarter ended March 31, 2023.
- Original 8-K transcript erroneously included extraneous tabular data in Australian Dollars; this amendment corrects that error.
- Further details available in Form 10-Q filed May 11, 2023.

## SEC filing metadata
- accession: 0001193125-23-145360
- form_type: 8-K/A
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312523145360/0001193125-23-145360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312523145360/d489389d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145360
- JSON: https://secwatch.observer/filing/0001193125-23-145360.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145360.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported fiscal quarter ended March 31, 2023 results: revenue $10.6 million, net income $9.2 million, EPS $0.37 per share.
  - Period: fiscal quarter ended March 31, 2023
  - Revenue: $10.6 million
  - Net income: $9.2 million
  - EPS: $0.37 per share
  - Result: reported results
  source text: Item 2.02. Results of Operations and Financial Condition. On May 12, 2023, AVITA Medical, Inc. (the “Company”) furnished a Current Report on Form 8-K (the “Original Form 8-K”) with a transcript of the Company’s May 11, 2023 conference call discussing the Company’s financial results for its fiscal quarter ended March 31, 2023 as Exhibit 99.2. Exhibit 99.2 to the Original Form 8-K inadvertently included extraneous tabular information from S&P Global Market Intelligence, including financial results and consensus data for the quarter ended March 31, 2023 in Australian Dollars. The Company’s actual results are reported in U.S. Dollars and included $10.6 million in revenue and a net loss of $9.2 million, or $0.37 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312523145360/0001193125-23-145360-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.